HC Wainwright Reaffirms “Buy” Rating for Opus Genetics (NASDAQ:IRD)

Opus Genetics (NASDAQ:IRD)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright also issued estimates for Opus Genetics’ Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.24) EPS and FY2029 earnings at $0.00 EPS.

Opus Genetics Stock Up 2.5 %

IRD opened at $0.93 on Tuesday. The company has a market cap of $29.89 million, a P/E ratio of -0.86 and a beta of 0.28. The stock has a fifty day moving average price of $1.07. Opus Genetics has a one year low of $0.81 and a one year high of $1.56.

Opus Genetics (NASDAQ:IRD) last released its earnings results on Monday, March 31st. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.93). Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%. The firm had revenue of $3.40 million for the quarter, compared to analyst estimates of $11.10 million. Research analysts expect that Opus Genetics will post -1.22 earnings per share for the current fiscal year.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.